Total Payments
$1.1M
2024 Payments
$46,937
Companies
32
Transactions
137
Payment Breakdown by Category
Research$1.1M (99.4%)
Consulting$2,250 (0.2%)
Food & Beverage$1,836 (0.2%)
Other$1,120 (0.1%)
Travel$958.01 (0.1%)
Education$91.99 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.1M | 51 | 99.4% |
| Consulting Fee | $2,250 | 2 | 0.2% |
| Food and Beverage | $1,836 | 78 | 0.2% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1,120 | 1 | 0.1% |
| Travel and Lodging | $958.01 | 3 | 0.1% |
| Education | $91.99 | 2 | 0.0% |
Payments by Type
Research
$1.1M
51 transactions
General
$6,256
86 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Bausch Health US, LLC | $1.0M | 21 | $0 (2021) |
| Nielsen BioSciences, Inc. | $44,559 | 1 | $0 (2024) |
| Taro Pharmaceuticals USA, Inc. | $15,318 | 6 | $0 (2018) |
| Allergan Inc. | $2,391 | 10 | $0 (2019) |
| Biofrontera Inc. | $2,272 | 3 | $0 (2024) |
| Endo Pharmaceuticals Inc. | $1,849 | 11 | $0 (2018) |
| PFIZER INC. | $1,441 | 12 | $0 (2019) |
| LEO Pharma AS | $1,003 | 5 | $0 (2018) |
| Janssen Biotech, Inc. | $168.50 | 6 | $0 (2019) |
| ABBVIE INC. | $160.63 | 3 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $46,937 | 4 | Nielsen BioSciences, Inc. ($44,559) |
| 2023 | $22.92 | 1 | GENZYME CORPORATION ($22.92) |
| 2021 | $45.00 | 1 | Bausch Health US, LLC ($45.00) |
| 2019 | $925,875 | 29 | Bausch Health US, LLC ($924,558) |
| 2018 | $116,991 | 50 | Bausch Health US, LLC ($111,123) |
| 2017 | $16,025 | 52 | TARO PHARMACEUTICALS USA, INC. ($15,295) |
All Payment Transactions
137 individual payment records from CMS Open Payments — Page 1 of 6
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/06/2024 | Biofrontera Inc. | AMELUZ (Drug), BF-RhodoLED, XEPI | Consulting Fee | Cash or cash equivalent | $750.00 | General |
| Category: DERMATOLOGY | ||||||
| 11/30/2024 | Nielsen BioSciences, Inc. | Candin (Biological) | — | Cash or cash equivalent | $44,559.27 | Research |
| Study: CFW-3A • Category: Immunotherapy | ||||||
| 06/14/2024 | Biofrontera Inc. | AMELUZ (Drug), BF-RhodoLED, XEPI | Consulting Fee | Cash or cash equivalent | $1,500.00 | General |
| Category: DERMATOLOGY | ||||||
| 03/15/2024 | ABBVIE INC. | BOTOX (Biological) | — | In-kind items and services | $127.87 | Research |
| Study: BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study • Category: FACIAL AESTHETICS | ||||||
| 11/07/2023 | GENZYME CORPORATION | — | Food and Beverage | In-kind items and services | $22.92 | General |
| 06/03/2021 | Bausch Health US, LLC | — | Food and Beverage | In-kind items and services | $45.00 | General |
| 08/23/2019 | Bausch Health US, LLC | — | — | Cash or cash equivalent | $20,650.00 | Research |
| Study: A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLECONTROLLED, PARALLEL-GROUP, CLINICAL STUDY COMPARING THE EFFICACY AND SAFETY OF IDP-126 GEL IN THE TREATMENT OF ACNE VULGARIS | ||||||
| 08/23/2019 | Bausch Health US, LLC | — | — | Cash or cash equivalent | $20,650.00 | Research |
| Study: A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLECONTROLLED, PARALLEL-GROUP, CLINICAL STUDY COMPARING THE EFFICACY AND SAFETY OF IDP-126 GEL IN THE TREATMENT OF ACNE VULGARIS | ||||||
| 08/23/2019 | Bausch Health US, LLC | — | — | Cash or cash equivalent | $10,250.00 | Research |
| Study: A PHASE 1B OPEN-LABEL STUDY EVALUATING THE ABSORPTION AND SYSTEMIC PHARMACOKINETICS OF TOPICALLY APPLIED IDP-126 GEL IN COMPARISON WITH EPIDUO FORTE GEL IN SUBJECTS WITH MODERATE TO SEVERE ACNE VULGARIS UNDER MAXIMAL USE CONDITIONS | ||||||
| 08/23/2019 | Bausch Health US, LLC | — | — | Cash or cash equivalent | $9,867.39 | Research |
| Study: A PHASE 1B OPEN-LABEL STUDY EVALUATING THE ABSORPTION AND SYSTEMIC PHARMACOKINETICS OF TOPICALLY APPLIED IDP-126 GEL IN COMPARISON WITH EPIDUO FORTE GEL IN SUBJECTS WITH MODERATE TO SEVERE ACNE VULGARIS UNDER MAXIMAL USE CONDITIONS | ||||||
| 08/05/2019 | Bausch Health US, LLC | — | — | Cash or cash equivalent | $9,867.39 | Research |
| Study: A PHASE 1B OPEN-LABEL STUDY EVALUATING THE ABSORPTION AND SYSTEMIC PHARMACOKINETICS OF TOPICALLY APPLIED IDP-126 GEL IN COMPARISON WITH EPIDUO FORTE GEL IN SUBJECTS WITH MODERATE TO SEVERE ACNE VULGARIS UNDER MAXIMAL USE CONDITIONS | ||||||
| 07/14/2019 | Allergan Inc. | — | — | In-kind items and services | $89.05 | Research |
| Study: BOTOX onabotulinumtoxinA Treatment of Masseter Muscle Prominence A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study | ||||||
| 07/14/2019 | Allergan Inc. | — | — | In-kind items and services | $28.61 | Research |
| Study: BOTOX onabotulinumtoxinA Treatment of Masseter Muscle Prominence A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study | ||||||
| 07/13/2019 | Allergan Inc. | — | — | In-kind items and services | $126.73 | Research |
| Study: BOTOX onabotulinumtoxinA Treatment of Masseter Muscle Prominence A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study | ||||||
| 07/13/2019 | Allergan Inc. | — | — | In-kind items and services | $7.39 | Research |
| Study: BOTOX onabotulinumtoxinA Treatment of Masseter Muscle Prominence A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study | ||||||
| 07/13/2019 | Allergan Inc. | — | — | In-kind items and services | $4.99 | Research |
| Study: BOTOX onabotulinumtoxinA Treatment of Masseter Muscle Prominence A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study | ||||||
| 07/12/2019 | Allergan Inc. | — | — | In-kind items and services | $822.19 | Research |
| Study: BOTOX onabotulinumtoxinA Treatment of Masseter Muscle Prominence A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study | ||||||
| 07/12/2019 | Allergan Inc. | — | — | In-kind items and services | $24.56 | Research |
| Study: BOTOX onabotulinumtoxinA Treatment of Masseter Muscle Prominence A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study | ||||||
| 07/12/2019 | Allergan Inc. | — | — | In-kind items and services | $21.46 | Research |
| Study: BOTOX onabotulinumtoxinA Treatment of Masseter Muscle Prominence A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study | ||||||
| 06/07/2019 | Bausch Health US, LLC | — | — | Cash or cash equivalent | $32,500.00 | Research |
| Study: A PHASE 1B OPEN-LABEL STUDY EVALUATING THE ABSORPTION AND SYSTEMIC PHARMACOKINETICS OF TOPICALLY APPLIED IDP-126 GEL IN COMPARISON WITH EPIDUO FORTE GEL IN SUBJECTS WITH MODERATE TO SEVERE ACNE VULGARIS UNDER MAXIMAL USE CONDITIONS | ||||||
| 04/12/2019 | Bausch Health US, LLC | — | — | Cash or cash equivalent | $120,000.00 | Research |
| Study: A PHASE 1B OPEN-LABEL STUDY EVALUATING THE ABSORPTION AND SYSTEMIC PHARMACOKINETICS OF TOPICALLY APPLIED IDP-126 GEL IN COMPARISON WITH EPIDUO FORTE GEL IN SUBJECTS WITH MODERATE TO SEVERE ACNE VULGARIS UNDER MAXIMAL USE CONDITIONS | ||||||
| 03/20/2019 | Aclaris Therapeutics, Inc. | RHOFADE (Drug) | Food and Beverage | In-kind items and services | $22.32 | General |
| Category: DERMATOLOGY | ||||||
| 03/14/2019 | PFIZER INC. | EUCRISA (Drug) | Food and Beverage | In-kind items and services | $15.16 | General |
| Category: DERMATOLOGY | ||||||
| 03/12/2019 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $31.53 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 03/08/2019 | Bausch Health US, LLC | — | — | Cash or cash equivalent | $2,173.22 | Research |
| Study: A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLECONTROLLED, PARALLEL-GROUP, CLINICAL STUDY COMPARING THE EFFICACY AND SAFETY OF IDP-126 GEL IN THE TREATMENT OF ACNE VULGARIS | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 1B OPEN-LABEL STUDY EVALUATING THE ABSORPTION AND SYSTEMIC PHARMACOKINETICS OF TOPICALLY APPLIED IDP-126 GEL IN COMPARISON WITH EPIDUO FORTE GEL IN SUBJECTS WITH MODERATE TO SEVERE ACNE VULGARIS UNDER MAXIMAL USE CONDITIONS | Bausch Health US, LLC | $432,735 | 6 |
| A PHASE 1B OPEN-LABEL STUDY EVALUATING THE ABSORPTION AND SYSTEMIC PHARMACOKINETICS OF TOPICALLY APPLIED IDP-135 CREAM IN SUBJECTS WITH ACNE VULGARIS UNDER MAXIMAL USE CONDITIONS | Bausch Health US, LLC | $427,700 | 2 |
| A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLECONTROLLED, PARALLEL-GROUP, CLINICAL STUDY COMPARING THE EFFICACY AND SAFETY OF IDP-126 GEL IN THE TREATMENT OF ACNE VULGARIS | Bausch Health US, LLC | $170,770 | 9 |
| CFW-3A | Nielsen BioSciences, Inc. | $44,559 | 1 |
| TaroAZAG 1533 | TARO PHARMACEUTICALS USA, INC. | $15,295 | 5 |
| A Phase 1b Open-Label, Randomized Study Evaluating the Absorption and Systemic Pharmacokinetics of Topically Applied IDP-126 Gel in Comparison with EpiDuo Forte Gel 0.3 adapalene2.5 BPO in Subjects with Acne Vulgaris under Maximal Use Conditions | Bausch Health US, LLC | $3,000 | 1 |
| A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of EN3835 In The Treatment Of Edematous Fibrosclerotic Panniculopathy Cellulite | Endo Pharmaceuticals Inc. | $1,849 | 11 |
| A Phase 3, Multi-Center, Randomized, Double-Blind, Vehicle-Controlled, 2 Arm, Parallel Group Study Comparing the Safety and Efficacy of IDP-120 Gel and IDP-120 Vehicle Gel in the Treatment of Acne Vulgaris | Bausch Health US, LLC | $1,476 | 2 |
| BOTOX onabotulinumtoxinA Treatment of Masseter Muscle Prominence A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study | Allergan Inc. | $1,125 | 8 |
| TRALOKINUMAB VACCINE RESPONSE TIME | LEO Pharma AS | $1,003 | 5 |
| BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study | ABBVIE INC. | $127.87 | 1 |
About Dr. Janet Dubois, M.D
Dr. Janet Dubois, M.D is a Dermatology healthcare provider based in Austin, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/03/2006. The National Provider Identifier (NPI) number assigned to this provider is 1295797504.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Janet Dubois, M.D has received a total of $1.1M in payments from pharmaceutical and medical device companies, with $46,937 received in 2024. These payments were reported across 137 transactions from 32 companies. The most common payment nature is "" ($1.1M).
Ad
Practice Information
- Specialty Dermatology
- Location Austin, TX
- Active Since 04/03/2006
- Last Updated 07/08/2007
- Taxonomy Code 207N00000X
- Entity Type Individual
- NPI Number 1295797504
Products in Payments
- Candin (Biological) $44,559
- Topicort Spray 0.25% (Drug) $15,295
- AMELUZ (Drug) $2,250
- BOTOX (Biological) $127.87
- EUCRISA (Drug) $127.76
- COSENTYX (Biological) $97.30
- Tremfya (Drug) $93.44
- DORYX (Drug) $88.03
- DERMATITIS - DISEASE (Drug) $67.50
- DUPIXENT (Biological) $60.53
- Xolegel (Drug) $56.94
- ENSTILAR (Drug) $55.03
- DUPIXENT DUPILUMAB INJECTION (Biological) $53.41
- Enbrel (Biological) $45.25
- STELARA (Biological) $43.75
- Cimzia (Drug) $43.01
- Veltin (Drug) $42.77
- SOOLANTRA (Drug) $42.47
- Otezla (Drug) $38.79
- Humira (Biological) $32.76
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Dermatology Doctors in Austin
Dr. Edward Lain, M.d, M.D
Dermatology — Payments: $2.3M
Dermatology $2.3M
Daniel Carrasco, Md, MD
Dermatology — Payments: $1.2M
Dermatology $1.2M
Dale Schaefer, Md, MD
Dermatology — Payments: $1.2M
Dermatology $1.2M
Ms. Heidi Prather, M.d, M.D
Dermatology — Payments: $530,857
Dermatology $530,857
Daniel Friedmann, M.d, M.D
Dermatology — Payments: $231,608
Dermatology $231,608
Dr. Jennifer Gordon, Md, MD
Dermatology — Payments: $161,696
Dermatology $161,696